IA
ACTU

IFP Advisors’s Actuate Therapeutics ACTU Stock Holding History

IFP Advisors’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112 Buy
73
+72
+7,200% +$167 ﹤0.01% 4947
2026
Q1 		$3 Buy
+1
New +$4 ﹤0.01% 5006

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

IFP Advisors's ACTU Position: Q2 2026 in Review

IFP Advisors increased its Actuate Therapeutics (ACTU) stake by 7,200% in Q2 2026, buying an estimated $167 and bringing the position to 73 shares worth $112. The position accounts for ﹤0.01% of the portfolio, ranked #4947.

IFP Advisors first reported a position in ACTU in Q1 2026 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • IFP Advisors held 73 shares of Actuate Therapeutics worth $112 as of Q2 2026.
  • IFP Advisors bought 72 Actuate Therapeutics shares in Q2 2026, an estimated $167.
  • Actuate Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4947 holding.
  • IFP Advisors first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.